Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact

Isin GB0009252882
Ticker GSK.L
Currency £
Aware Investor Index (AII) 290.7452
Recommendation STRONG BUY
P/E 44.99
ROE 100.00 %
Capitalization 293,410,164,996 $
Dividend Yield 2.09 %
P/S 9.76
AII Position 14
P/E Position 570
ROE Position 28
Capitalization Position 16
Dividend Yield Position 308
Sales 23,923,000,000 £
10-Year Average Earnings 5,192,400,000 £
Shares Outstanding 4,888,000,000
Equity 5,114,000,000 £
Dividend per Share 1 £
Industry Pharmaceutical
Country Great Britain
GLAXOSMITHKLINE Investor Relations Web Site http://www.gsk.com/investors.html


2015 12 23,923,000,000.00 £
2014 12 23,006,000,000.00 £
2013 12 26,505,000,000.00 £


2015 12 8,422,000,000.00 £
2014 12 2,756,000,000.00 £
2013 12 5,436,000,000.00 £
2012 12 4,499,000,000.00 £
2011 12 5,208,000,000.00 £
2010 12 2,961,000,000.00 £
2009 12 6,283,000,000.00 £
2008 12 5,551,000,000.00 £
2007 12 5,310,000,000.00 £
2006 12 5,498,000,000.00 £


2015 12 5,114,000,000.00 £
2014 12 4,263,000,000.00 £
2013 12 7,812,000,000.00 £
2012 12 6,747,000,000.00 £
2011 12 8,827,000,000.00 £
2010 12 9,745,000,000.00 £
2009 12 10,742,000,000.00 £
2008 12 8,318,000,000.00 £
2007 12 9,910,000,000.00 £
2006 12 9,648,000,000.00 £

Shares Outstanding:

2015 12 4,888,000,000
2014 12 4,865,000,000
2013 12 4,919,000,000
2012 12 4,913,000,000
2011 12 5,099,000,000
2010 12 5,128,000,000
2009 12 5,108,000,000
2008 12 5,226,000,000
2007 12 5,567,000,000
2006 12 5,700,000,000


Bloomberg News for GLAXOSMITHKLINE:

Mar 6, 2018
Tiny U.K. Biotech Takes On Glaxo’s $730,000 Gene Therapy
GlaxoSmithKline Plc has seen precious few takers for its $730,000 gene therapy for a rare and life-threatening immune illness known as “bubble-boy disease.” Now a tiny startup thinks it can succeed...
Feb 28, 2018
Scientists Want to Completely Rethink How They Make the Flu Vaccine
ahead. Leading the charge from Big Pharma are drugmaking giants, including GlaxoSmithKline PLC, Sanofi SA and Johnson & Johnson.Sanofi, the world’s biggest flu-vaccine maker, signed a deal with SK...
Dec 10, 2017
Bluebird, Celgene Myeloma Therapy Appears to Improve in Time
responded, including one entering remission. A separate first-in-human study showed GlaxoSmithKline Plc’s GSK2857916, a traditional biotechnology medicine that targets BCMA with an attached chemotherapy...
Dec 11, 2017
Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled it will look to speed development of an experimental cancer treatment as part of its ambition to expand in oncology just two years after...
Dec 14, 2015
Amgen Reacquires Drug Rights From Glaxo in Plan to Grow Abroad
drug recently approved in Europe.“Amgen originally partnered with GSK in these international expansion markets to capitalize on GSK’s established presence in these markets,” said Amgen spokeswoman...
Feb 2, 2016
Axovant Deflates After Pfizer Fails on Alzheimer's
abandoned its own effort long before Pfizer. There is previous clinical trial data as well from GSK and Lundbeck and Otsuka, which are co-developing a similar drug. Their approach so far only seems...
Aug 9, 2016
Libor Fines and Robot Analysts
they put a fleece on the AI. For some reason "Emma will start trading stocks from pharma giant GSK and Tesla along with U.S. Treasury bonds," which seems like sort of a limited coverage universe...
Mar 5, 2014
Glaxo Preparing With J&J to Test Once-a-Month AIDS Drugs
GlaxoSmithKline Plc and Johnson & Johnson are preparing to test the first monthly injections of experimental AIDS drugs in a study that may transform the treatment of the deadly disease. The study...
Nov 30, 2014
Glaxo Is Said Close to Announcing Reorganization, U.S. Job Cuts
GlaxoSmithKline Plc is planning a reorganization that will include hundreds of job cuts in the U.S., where the drugmaker is struggling to sell respiratory medicines, people familiar with the situation...
Apr 30, 2014
Glaxo Happy to Be ‘Interested Observer’ of Astra Sale
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, is happy to remain an “interested observer” rather than get involved in the potential sale of rival AstraZeneca Plc, Chief Executive Officer Andrew...


Street Confidential - 19 hours ago
Poised For a Move? Glaxosmithkline Plc (GSK.L) See Shares Move ...
Shares of Glaxosmithkline Plc (GSK.L) are moving on volatility today -0.11% or -1.40 from the open. The LSE listed company saw a recent bid of 1300.40 on 1080154 volume. Stock market investors are typically searching for solid quality companies to help boost the portfolio. There are plenty of quality ...
Stanley Business News
4 stocks for my retirement portfolio? GlaxoSmithKline plc, Taylor ...
GlaxoSmithKline plc, Taylor Wimpey plc, Aviva plc and Barclays PLC ... Retirement is still some way off for me, but I'm thinking about the long-term potential of GlaxoSmithKline plc (LON:GSK) (GSK.L) ... With a 6% dividend yield, GlaxoSmithKline remains one of the highest-yielding stocks in the Footsie.
Investomania (blog) - 23 hours ago
UnitedHealth names former GSK CEO Andrew Witty as Optum head
(Reuters) - Health insurer UnitedHealth Group Inc (UNH.N) on Tuesday named its board member and former GlaxoSmithKline Plc (GSK.L) head Andrew Witty as chief executive of its pharmacy benefit unit, Optum, effective July 1. Sir Andrew Witty, attends the World Economic Forum (WEF) annual meeting ...
Reuters - 13 Mar 2018
Glaxosmithkline Plc (GSK.L) Technicals Take Center Stage
Investors are paying close attention to the charts of Glaxosmithkline Plc (GSK.L), as the shares are holding above the MACD Histogram zero line. The equity recently moved 12.20, touching 1323.40 on a recent tick. MACD-Histogram bridges the time gap between the price movement and MACD. It offers a ...
Stanley Business News - 1 day ago
Investors Sizing Up Glaxosmithkline Plc (GSK.L) As Shares Move ...
Shares of Glaxosmithkline Plc (GSK.L) have seen the needle move 0.93% or 12.20 in the most recent session. The LSE listed company saw a recent bid of 1323.40 on 13890000 volume. Even for seasoned investors, it can be natural to become wary when certain stocks are tanking in the stock portfolio.
Danvers Record - 2 days ago
Indicator Check: Wilder Moving Average is Below SMA on Shares of ...
At the time of writing, Glaxosmithkline Plc (GSK.L) has a 14-day ATR of 21.07. The average true range indicator was created by J. Welles Wilder in order to measure volatility. The ATR may assist traders with figuring out the strength of a breakout or reversal in price. It is important to note that the ATR was not ...
Saline News - 18 hours ago
5 top growth stocks? HSBC Holdings plc, GlaxoSmithKline plc, J ...
Growth stocks continue to be my main focus within the investment world, which is why I'm considering the prospects of HSBC Holdings plc (LON:HSBA) (HSBA.L), GlaxoSmithKline plc (LON:GSK) (GSK.L), J Sainsbury plc (LON:SBRY) (SBRY.L), Petrofac Limited (LON:PFC) (PFC.L) and Fevertree Drinks PLC (LON:FEVR) ...
Investomania (blog) - 1 day ago
4 shares capable of beating the Footsie? BT Group plc ...
The company has a diverse set of operations which could help it to offer defensive characteristics. If markets remain volatile, then it could become a more popular stock. Since GlaxoSmithKline has a dividend yield of around 6%, it may also see demand for its shares rise if inflation remains stubbornly high.
Investomania (blog) - 4 days ago
Do National Grid plc, Diageo plc, Unilever plc, GlaxoSmithKline plc ...
This could make the stock more appealing as inflation moves higher, while its defensive characteristics could be attractive if investor volatility remains high. Therefore, I'm upbeat about National Grid's outlook. GlaxoSmithKline could also perform well in future. The company has a pipeline that has been the ...
Investomania (blog) - 6 days ago
Glaxosmithkline Plc (GSK.L) Chikou Pounds Ahead of the Tenkan
Glaxosmithkline Plc (GSK.L) are under the spotlight as the Chikou span line has crossed above the Tenkan line. The Ichimoku signals, indeed all Ichimoku elements, should never be taken in isolation, but considered in the context of the overall chart. Ichimoku Kinko Hyo is a visual technical analysis system ...